Who makes ATB-101, ATB-1011, ATB-1012?

ATB-101, ATB-1011, ATB-1012 is developed by Autotelicbio.

What development phase is ATB-101, ATB-1011, ATB-1012 in?

ATB-101, ATB-1011, ATB-1012 is in Phase 1.

Last reviewed 2026-04-20 · How we verify

ATB-101, ATB-1011, ATB-1012

Autotelicbio · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	ATB-101, ATB-1011, ATB-1012
Also known as	ATB-1011 brand name: Olmetec, ATB-1012 brand name: Forxiga
Sponsor	Autotelicbio
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ATB-101, ATB-1011, ATB-1012 CI brief — competitive landscape report
ATB-101, ATB-1011, ATB-1012 updates RSS · CI watch RSS
Autotelicbio portfolio CI